Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Candida auris, a multidrug-resistant yeast that causes invasive infections, was first described in 2009 in Japan and has since been reported from several countries. METHODS: To understand the global emergence and epidemiology of C. auris, we obtained isolates from 54 patients with C. auris infection from Pakistan, India, South Africa, and Venezuela during 2012-2015 and the type specimen from Japan. Patient information was available for 41 of the isolates. We conducted antifungal susceptibility testing and whole-genome sequencing (WGS). RESULTS: Available clinical information revealed that 41% of patients had diabetes mellitus, 51% had undergone recent surgery, 73% had a central venous catheter, and 41% were receiving systemic antifungal therapy when C. auris was isolated. The median time from admission to infection was 19 days (interquartile range, 9-36 days), 61% of patients had bloodstream infection, and 59% died. Using stringent break points, 93% of isolates were resistant to fluconazole, 35% to amphotericin B, and 7% to echinocandins; 41% were resistant to 2 antifungal classes and 4% were resistant to 3 classes. WGS demonstrated that isolates were grouped into unique clades by geographic region. Clades were separated by thousands of single-nucleotide polymorphisms, but within each clade isolates were clonal. Different mutations in ERG11 were associated with azole resistance in each geographic clade. CONCLUSIONS: C. auris is an emerging healthcare-associated pathogen associated with high mortality. Treatment options are limited, due to antifungal resistance. WGS analysis suggests nearly simultaneous, and recent, independent emergence of different clonal populations on 3 continents. Risk factors and transmission mechanisms need to be elucidated to guide control measures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“C. auris, a novel Candida species first identified in 2009, has emerged since 2013 as a cause of nosocomial outbreaks in multiple countries across 5 continents.”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [16]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resistance to all three classes of antifungals is reported most commonly in India in South Asia (3%), whereas this is much less common in other regions of the world.122–124”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [122]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Invasive C. auris infections are associated with high mortality rates, with 60% of hospitalizations due to C. auris infections resulting in death (8).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three such mutations, encoding the amino acid substitutions VF125AL (commonly referred to as F126L), Y132F, and K143R, are frequently reported among fluconazole-resistant clinical isolates, and associations between these mutations and specific genetic clades of C. auris have been observed (2).”
From Mutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, up to 96% of C. auris may exhibit resistance to fluconazole, an exceptionally high value compared to 0.5–2% for C. albicans, 4–9% for C. tropicalis, 2–6% for C. parapsilosis, and 11–13% for C. glabrata [16,40,41].”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [16]
Experimental — accuracy not yet measured
29 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0
Tamura, K., Stecher, G., Peterson, D., Filipski, A., & Kumar, S. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst197 · Cited by 47,205
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895 · cited 1×
“SNPs were identified using 2 independent pipelines, as described elsewhere (see also the legend to Supplemental Figure 1) [15, 19].”
MethodEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“auris because we did not have a comparison group of patients with other Candida infections from the same institutions [31].”
BackgroundResultNonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data
Chin, C.-S., Alexander, D. H., Marks, P., Klammer, A. A., Drake, J., Heiner, C., Clum, A., Copeland, A., Huddleston, J., Eichler, E. E., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2474 · Cited by 4,029 · cited 1×
“The reference genome was generated by de novo assembly of PacBio reads from isolate B8441, as described elsewhere [18], and used as a reference for single-nucleotide polymorphism (SNP) calling.”
MethodSatoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381 · cited 8×
“To understand the global emergence and epidemiology of C. auris, we obtained isolates from 54 patients with C. auris infection from Pakistan, India, South Africa, and Venezuela during 2012–2015 and the type specimen from Japan.”
BackgroundInfluentialEvolution of pathogenicity and sexual reproduction in eight Candida genomes
Butler, G., Rasmussen, M. D., Lin, M. F., Santos, M. A. S., Sakthikumar, S., Munro, C. A., Rheinbay, E., Grabherr, M., Forche, A., Reedy, J. L., et al. (2009) · Nature · doi:10.1038/nature08064 · Cited by 1,065 · cited 1×
“5 Mb, similar to that of other Candida species [25].”
BackgroundSelf-citationKathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00367-15 · Cited by 532 · cited 1×
“It phenotypically resembles Candida haemulonii and requires use of molecular methods for identification [9, 10].”
MethodSelf-citationFirst Three Reported Cases of Nosocomial Fungemia Caused by Candida auris
Lee, W. G., Shin, J. H., Uh, Y., Kang, M. G., Kim, S. H., Park, K. H., & Jang, H.-C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00319-11 · Cited by 523 · cited 2×
“auris [3], establishing that this new species was capable of causing invasive infections.”
BackgroundPerea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470
Incidence, characteristics and outcome of ICU-acquired candidemia in India
Chakrabarti, A., Sood, P., Rudramurthy, S. M., Chen, S., Kaur, H., Capoor, M., Chhina, D., Rao, R., Eshwara, V. K., Xess, I., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-014-3603-2 · Cited by 454 · cited 1×
“auris may become widely established within certain regions, as evidenced by the fact that it now accounts for nearly 5% of candidemia in Indian intensive care units [5].”
Background
Cited by
Items 501–600 of 1,007
Chen, Y., Wu, X., Xu, C., Huang, J., Zhang, L., Qiu, P., Zheng, D., Chen, W., & Zhang, S. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5614 · Cited by 36
“…through genetic colocalization of ssa1 (encoding a heat shock protein, HSP70) and ERG11 (encoding lanosterol 14 α ‑demethylase, a target of azole antifungals), allowing survival in hospital envi‑ ronments with high heat stability and decreased fluconazole binding due to ERG11 mutations (74,77,78).”
Kovács, R., Nagy, F., Tóth, Z., Forgács, L., Tóth, L., Váradi, G., Tóth, G. K., Vadászi, K., Borman, A. M., Majoros, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020771 · Cited by 36
Salah, H., Sundararaju, S., Dalil, L., Salameh, S., Al-Wali, W., Tang, P., Abid, F. B., & Tsui, C. K. M. (2021) · Journal of Fungi · doi:10.3390/jof7030240 · Cited by 36
Kelly, M., Pasmans, F., Muñoz, J. F., Shea, T., Carranza, S., Cuomo, C. A., & Martel, A. (2021) · Nature Communications · doi:10.1038/s41467-021-27005-0 · Cited by 39
Self-citationSnayd, M., Dias, F., Ryan, R., Clout, D., & Banach, D. B. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00080-18 · Cited by 37
Probiotics as antifungal agents: Experimental confirmation and future prospects
Kosgey, J. C., Jia, L., Fang, Y., Yang, J., Gao, L., Wang, J., Nyamao, R. M., Cheteu, M., Tong, D., Wekesa, V. W., et al. (2019) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2019.05.001 · Cited by 38
Almaghrabi, R. S., Albalawi, R., Mutabagani, M., Atienza, E., Aljumaah, S., Gade, L., Forsberg, K., Litvintseva, A., & Althawadi, S. (2020) · Mycoses · doi:10.1111/myc.13065 · Cited by 34
Self-citationMunshi, A., Almadani, F., Ossenkopp, J., Alharbi, M., Althaqafi, A., Alsaedi, A., Al-Amri, A., & Almarhabi, H. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.11.021 · Cited by 34
Epigenetic Regulation of Antifungal Drug Resistance
Patra, S., Raney, M., Pareek, A., & Kaur, R. (2022) · Journal of Fungi · doi:10.3390/jof8080875 · Cited by 38
McCormick, T. S., & Ghannoum, M. A. (2024) · Pathogens and Immunity · doi:10.20411/pai.v8i2.656 · Cited by 37
“This changed in 2009 with the emergence of C. auris [12].”
BackgroundMartínez-Murcia, A., Navarro, A., Bru, G., Chowdhary, A., Hagen, F., & Meis, J. F. G. M. (2018) · Mycoses · doi:10.1111/myc.12834 · Cited by 36
Self-citationThe Epidemiology and Prevention of Candida auris
Snyder, G. M., & Wright, S. B. (2019) · Current Infectious Disease Reports · doi:10.1007/s11908-019-0675-8 · Cited by 37
The estimated burden of fungal disease in South Africa
Schwartz, I. S., Boyles, T. H., Kenyon, C. R., Hoving, J. C., Brown, G. D., & Denning, D. W. (2019) · South African Medical Journal · doi:10.7196/samj.2019.v109i11.13718 · Cited by 42
Advances in Fungal Peptide Vaccines
da Silva, L. B. R., Taborda, C. P., & Nosanchuk, J. D. (2020) · Journal of Fungi · doi:10.3390/jof6030119 · Cited by 35
“auris, which is an emerging, multi-drug resistant species [81,82] that has marked biological differences from C.”
BackgroundCandida aurisColonization After Discharge to a Community Setting: New York City, 2017–2019
Bergeron, G., Bloch, D., Murray, K., Kratz, M. M., Parton, H. B., Ackelsberg, J., Antwi, M., Rosso, P. D., Dorsinville, M. S., Kubinson, H., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa620 · Cited by 34
“Screening cases were patients with positive C auris cultures but without clinical illnesses from C auris; they were identified during contact tracing, admission screening, or applyparastyle “fig//caption/p[1]” parastyle “FigCapt””
BackgroundThe Antibiofilm Role of Biotics Family in Vaginal Fungal Infections
Boahen, A., Than, L. T. L., Loke, Y.-L., & Chew, S. Y. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.787119 · Cited by 39
Wang, Y., & Xu, J. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.06.030 · Cited by 32
“Geographically, strains of Clades II and IV are predominantly found in East Asia and the Americas respectively while Clades I and III are predominantly from South Asia and Africa respectively.”
BackgroundInfluentialMaurice, A. D. S., Parti, U., Anikst, V. E., Harper, T., Mirasol, R., Dayo, A. J., Garner, O. B., Prabaker, K. K., & Yang, S. (2022) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2022.204 · Cited by 35
Kaki, R. (2023) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2023.2227218 · Cited by 37
Molecular Diagnostics in the Times of Surveillance for Candida auris
Kordalewska, M., & Perlin, D. S. (2019) · Journal of Fungi · doi:10.3390/jof5030077 · Cited by 38
“FKS1 S639P [54] or S639F [9,17] and ERG11 F126L, Y132F, or K143R [16,55,56] are the only mutations clearly linked to the clinical failure due to azole and echinocandin resistance, respectively.”
BackgroundTan, Y. E., Teo, J. Q.-M., Rahman, N. B. A., Ng, O. T., Marimuthu, K., Tan, A. L., Koh, T. H., & Ong, R. T. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.09.016 · Cited by 37
Zhang, Y., Zeng, L., Huang, X., Wang, Y., Chen, G., Moses, M., Zou, Y., Xiong, S., Xue, W., Dong, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59898-6 · Cited by 33
“Recent studies on the multidrug resistance of C. auris have revealed that over 90% of clinical isolates areresistant to fl uconazole, 30-41% areresistant to two classes of antifungal drugs, and approximately 4% are resistant to three or more 5,14,15 .”
Upc2-mediated mechanisms of azole resistance in Candida auris
Li, J., Aubry, L., Brandalise, D., Coste, A. T., Sanglard, D., & Lamoth, F. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03526-23 · Cited by 33
“3 INTRODUCTION 24 Candida auris is an emerging yeast pathogen that has spread in all continents since 2009 25 [1].”
BackgroundOrgan-specific mechanisms linking innate and adaptive antifungal immunity
Drummond, R. A., & Lionakis, M. S. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.01.008 · Cited by 37
“Moreover, there are worrying recent reports of emerging fungal pathogens with inherent resistance to our arsenal of available antifungal drugs [5].”
BackgroundEtxebeste, O., Otamendi, A., Garzia, A., Espeso, E. A., & Cortese, M. S. (2019) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2019.1630359 · Cited by 34
“This problem is compounded by the simultaneous emergence of the same pathogenic strain in different continents or local episodes of strains from distant locations (Islam et al. 2016; Malaker et al. 2016; Callaway 2016; Lockhart et al. 2017; Bhattacharya 2017).”
BackgroundKumar, M., Singh, A., Kumari, S., Kumar, P., Wasi, M., Mondal, A. K., Rudramurthy, S. M., Chakrabarti, A., Gaur, N. A., Gow, N. A. R., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158815 · Cited by 39
Khanina, A., Urbancic, K. F., Haeusler, G. M., Kong, D. C. M., Douglas, A. P., Tio, S. Y., Worth, L. J., Slavin, M. A., & Thursky, K. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa409 · Cited by 34
Fan, S., Zhan, P., Bing, J., Jiang, N., Huang, Y., Chen, D., Hu, T., Du, H., & Huang, G. (2021) · Virulence · doi:10.1080/21505594.2021.1928410 · Cited by 34
“Notably, a mutation of ERG11 (VF125AL, namely V125A and F126L) in BJCA002 has been previously reported as a hot-spot associated with fluconazole resistance [9,31].”
BackgroundMethodInfluentialMolecular Diagnosis of Yeast Infections
White, P. L., Price, J. S., Cordey, A., & Backx, M. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00421-x · Cited by 36
Narayanan, A., Selvakumar, P., Siddharthan, R., & Sanyal, K. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00634-22 · Cited by 36
John, L. L. H., Thomson, D. D., Bicanic, T. A., Hoenigl, M., Brown, A. J. P., Harrison, T. S., & Bignell, E. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01645-22 · Cited by 37
Ramos, R., Caceres, D. H., Perez, M., Garcia, N., Castillo, W., Santiago, E., Borace, J., Lockhart, S. R., Berkow, E. L., Hayer, L., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00371-18 · Cited by 32
Self-citationJenull, S., Shivarathri, R., Tsymala, I., Penninger, P., Trinh, P.-C., Nogueira, F., Chauhan, M., Singh, A., Petryshyn, A., Stoiber, A., et al. (2022) · mBio · doi:10.1128/mbio.00799-22 · Cited by 32
Self-citationTranscriptome Signatures Predict Phenotypic Variations of Candida auris
Jenull, S., Tscherner, M., Kashko, N., Shivarathri, R., Stoiber, A., Chauhan, M., Petryshyn, A., Chauhan, N., & Kuchler, K. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.662563 · Cited by 32
“The rapid and independent emergence of C. auris in different geographical locations (Lockhart et al., 2017; Chow et al., 2020), along with its pronounced pan-antifungal traits has sparked serious concerns.”
BackgroundZhao, G., Lyu, J., Veniaminova, N. A., Zarnowski, R., Mattos, E., Johnson, C. J., Quintanilla, D., Hautau, H., Hold, L. A., Xu, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60876-1 · Cited by 32
Antifungal Mechanism of Natural Products Derived from Plants: A Review
Long, N., & Li, F. (2024) · Natural Product Communications · doi:10.1177/1934578x241271747 · Cited by 42
Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways
Hetta, H. F., Melhem, T., Aljohani, H. M., Salama, A., Ahmed, R., Elfadil, H., Alanazi, F. E., Ramadan, Y. N., Battah, B., Rottura, M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18030364 · Cited by 35
“More recently, multidrug resistance (MDR) C. auris has become a signi fi cant global issue for public health due to its potential to result in hospital epidemics with high fatality rates [30,85,”
Successful treatment of C. auris shunt infection with intraventricular caspofungin
Singhal, T., Kumar, A., Borade, P. S., Shah, S., & Soman, R. N. (2018) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2018.08.005 · Cited by 35
Emergence of Candida auris in Russia
Barantsevich, N. E., Orlova, O. E., Shlyakhto, E. V., Johnson, E. M., Woodford, N., Lass-Floerl, C., Churkina, I. V., Mitrokhin, S. D., Shkoda, A. S., & Barantsevich, E. P. (2019) · Journal of Hospital Infection · doi:10.1016/j.jhin.2019.02.021 · Cited by 31
Wu, Y., Totten, M., Memon, W., Ying, C., & Zhang, S. X. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02063-19 · Cited by 32
Abe, M., Katano, H., Nagi, M., Higashi, Y., Sato, Y., Kikuchi, K., Hasegawa, H., & Miyazaki, Y. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243223 · Cited by 33
“Discussion Candida auris has recently been reported worldwide, and is believed to be a threat due to the potency of its multidrug-resistance and high virulence [11,15,16].”
BackgroundMonk, B. C., & Keniya, M. V. (2021) · Journal of Fungi · doi:10.3390/jof7020067 · Cited by 37
The Menace of Candida auris Epidemic Amidst the COVID-19 Pandemic: A Systematic Review
Najeeb, H., Siddiqui, S. A., Anas, Z., Ali, S. H., Usmani, S. U. R., Jawed, F., & Jatoi, H. N. (2022) · Diseases · doi:10.3390/diseases10030058 · Cited by 36
“It has rarely been isolated from the oral, esophageal, and gut mucosa of infected individuals [48].”
BackgroundSingh, S., Barbarino, A. M., Youssef, E. G., Coleman, D., Gebremariam, T., & Ibrahim, A. S. (2023) · Journal of Fungi · doi:10.3390/jof9010103 · Cited by 34
“) across all clades, thus making it difficult to develop new drug variants within the existing antifungal class (azoles, polyenes, and echinocandins) [1,24,25].”
BackgroundInfluentialHarnessing Whole Genome Sequencing in Medical Mycology
Cuomo, C. A. (2017) · Current Fungal Infection Reports · doi:10.1007/s12281-017-0276-7 · Cited by 32
Self-citationCandidemia from urinary tract source: the challenge of candiduria
Pemán, J., & Gaitán, A. C. R. (2018) · Hospital Practice · doi:10.1080/21548331.2018.1538623 · Cited by 39
Biofilms and beyond: Expanding echinocandin utility
Larkin, E. L., Dharmaiah, S., & Ghannoum, M. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx451 · Cited by 31
Kiyohara, M., Miyazaki, T., Okamoto, M., Hirayama, T., Makimura, K., Chibana, H., Nakada, N., Ito, Y., Sumiyoshi, M., Ashizawa, N., et al. (2023) · Journal of Fungi · doi:10.3390/jof9050529 · Cited by 32
“auris clinical isolates are resistant to fluconazole, 30–35% to amphotericin B, and 5–7% to echinocandins; multidrug resistance is observed in 41% of the isolates and pan-resistance (resistance to three antifungal classes) in 3–4% [16,17].”
BackgroundOne species, many faces: The underappreciated importance of strain diversity
Nysten, J. V., Sofras, D., & Dijck, P. V. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011931 · Cited by 30
“C . auris isolates fall into 5 genetically and geographically distinct clades [51,52].”
BackgroundGenomic epidemiology describes introduction and outbreaks of antifungal drug-resistant Candida auris
Kappel, D., Gifford, H., Brackin, A. P., Abdolrasouli, A., Eyre, D. W., Jeffery, K. J., Schelenz, S., Aanensen, D. M., Brown, C. S., Borman, A. M., et al. (2024) · npj Antimicrobials and Resistance · doi:10.1038/s44259-024-00043-6 · Cited by 37
“Clade II isolates, as well as the isolate from Iran (termed Clade V), are generally fl uconazole-susceptible, with clade-speci fi c patterns of azole antifungal resistance 5 , and varying susceptibility to amphotericin B, echinocandins and 5-fl ucytosine 15,31 – 33 .”
InfluentialMuñoz, J. E., Ramirez, L. M., Dias, L. D. S., Rivas, L. A., Ramos, L. S., Santos, A. L. S., Taborda, C. P., & Parra-Giraldo, C. M. (2020) · Journal of Fungi · doi:10.3390/jof6030104 · Cited by 31
“, fluconazole, itraconazole and voriconazole) [1].”
Viana, R., Dias, Ó., Lagoa, D., Galocha, M., Rocha, I., & Teixeira, M. C. (2020) · Journal of Fungi · doi:10.3390/jof6030171 · Cited by 36
“For example, in a recent case, Candida auris isolates were identified as resistant to the three classes of available antifungal drugs, further raising public concern on the future efficacy of current antifungal therapeutic options [13].”
BackgroundExperience of treating Candida auris cases at a general hospital in the state of Qatar
Shaukat, A., Ansari, N. A., Al-Wali, W., Karic, E., Madhoun, I. E., Mitwally, H., Hamed, M. M. M., & Visan, F. (2020) · IDCases · doi:10.1016/j.idcr.2020.e01007 · Cited by 36
“The all cause mortality among ur patients was 60 % which is in line with the mortality rate seen n other studies ranging from 30 to 60% [3].”
ResultDiagnostic Allele-Specific PCR for the Identification of Candida auris Clades
Carolus, H., Jacobs, S., Lobo Romero, C., Deparis, Q., Cuomo, C. A., Meis, J. F., & Van Dijck, P. (2021) · Journal of Fungi · doi:10.3390/jof7090754 · Cited by 29
“Clade II harbors the greatest percentage of drug-susceptible isolates [2], while clade I has the greatest reported percentage of MDR and pan-resistant isolates and is commonly resistant to fluconazole [2,13,18] and amphotericin B [2,13].”
BackgroundSelf-citationKhan, T., Suleman, M., Ali, S. S., Sarwar, M. F., Ali, I., Ali, L., Khan, A., Rokhan, B., Wang, Y., Zhao, R., et al. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105462 · Cited by 32
“auris has been isolated from patients admitted to the hospitals, and it has been reported that this pathogen favors colonizing the skin [16].”
Patwardhan, S. A., Prayag, A., Rajhans, P., Prayag, P. S., & Panchakshari, S. P. (2022) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-24152 · Cited by 36
Marathe, A., Zhu, Y., Chaturvedi, V. P., & Chaturvedi, S. (2022) · Mycopathologia · doi:10.1007/s11046-022-00656-3 · Cited by 32
In vitro synergy of isavuconazole in combination with colistin against Candida auris
Schwarz, P., Bidaud, A.-L., & Dannaoui, É. (2020) · Scientific Reports · doi:10.1038/s41598-020-78588-5 · Cited by 31
The skin mycobiome and intermicrobial interactions in the cutaneous niche
Tuor, M., & LeibundGut-Landmann, S. (2023) · Current Opinion in Microbiology · doi:10.1016/j.mib.2023.102381 · Cited by 30
Albahar, F., Alhamad, H., Assab, M. A., Abu-Farha, R., Alawi, L., & Khaleel, S. (2023) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed9010008 · Cited by 35
“Moreover, Candida auris was discovered in 2009 as an emerging multidrug-resistant pathogen, with cases or outbreaks reported in over 20 countries [10,11].”
BackgroundImportation, Mitigation, and Genomic Epidemiology of Candida auris at a Large Teaching Hospital
Lesho, E. P., Bronstein, M. Z., McGann, P., Stam, J., Kwak, Y., Maybank, R., McNamara, J., Callahan, M., Campbell, J., Hinkle, M. K., et al. (2018) · Infection Control & Hospital Epidemiology · doi:10.1017/ice.2017.231 · Cited by 29
“Although the genomic epidemiology of CA has been described at the global level, transmission dynamics of CA within individual hospitals remain poorly understood.(2,12) When a CA bloodstream infection was confirmed in a patient admitted 6 days previously to a 24-bed oncology ward, and who shared a room with another pat…”
BackgroundCandida auris colonization in an immunocompetent patient: A new threat in medical ICU
Das, S., Tigga, R. A., Rai, G., Singh, P. K., Datt, S., Tyagi, A., & Singh, N. P. (2018) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2018.05.004 · Cited by 30
“auris has shown minimal clonal difference [6,7].”
Epidemiology of antifungal susceptibility: Review of literature
Hadrich, I., & Ayadi, M. A. (2018) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2018.04.011 · Cited by 35
The First Two Cases of Candida auris in The Netherlands
Vogelzang, E. H., Weersink, A. J. L., van Mansfeld, R., Chow, N. A., Meis, J. F. G. M., & van Dijk, K. (2019) · Journal of Fungi · doi:10.3390/jof5040091 · Cited by 33
Self-citationOxadiazolylthiazoles as novel and selective antifungal agents
Hagras, M., Salama, E. A., Sayed, A. M., Abutaleb, N. S., Kotb, A., Seleem, M. N., & Mayhoub, A. S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112046 · Cited by 31
A decade after the emergence of Candida auris: what do we know?
ElBaradei, A. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03886-9 · Cited by 30
“Lanosterol 14-alpha-demethylase (LD) is encoded by ERG11, which converts lanosterol to ergosterol, the key fungal membrane component.”
BackgroundResultInfluentialCáceres, D. H., Rivera, S. M., Armstrong, P. A., Escandón, P., Chow, N. A., Ovalle, M. V., Díaz, J., Derado, G., Salcedo, S., Berrío, I., et al. (2020) · Mycopathologia · doi:10.1007/s11046-020-00478-1 · Cited by 32
Self-citationBanerjee, A., Pata, J., Sharma, S., Monk, B. C., Falson, P., & Prasad, R. (2021) · Journal of Fungi · doi:10.3390/jof7020068 · Cited by 34
“auris, the prophylactic or, prolonged use of antifungal drugs has allowed many other Candida species to manifest resistance to azoles, polyenes, echinocandins, and pyrimidine analogues [4,5].”
BackgroundCurrent and promising pharmacotherapeutic options for candidiasis
Scorzoni, L., Fuchs, B. B., Junqueira, J. C., & Mylonakis, E. E. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1873951 · Cited by 36
Nagy, F., Tóth, Z., Nyikos, F., Forgács, L., Jakab, Á., Borman, A. M., Majoros, L., & Kovács, R. (2021) · Medical Mycology · doi:10.1093/mmy/myab032 · Cited by 31
García‐Effrón, G. (2021) · Journal of Fungi · doi:10.3390/jof7030197 · Cited by 31
Shahi, G., Kumar, M., Skwarecki, A. S., Edmondson, M. B., Banerjee, A., Usher, J., Gow, N. A. R., Milewski, S., & Prasad, R. (2022) · The Cell Surface · doi:10.1016/j.tcsw.2022.100076 · Cited by 33
Bandara, N., & Samaranayake, L. P. (2022) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001548 · Cited by 33
Marena, G. D., Ramos, M. A. D. S., Carvalho, G. C., de Lima, L. C., do Nascimento, A. L. C. S., Sábio, R. M., Rodero, C. F., Spósito, L., Bauab, T. M., & Chorilli, M. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103566 · Cited by 33
Candida auris: descripción de un brote
García, C. S., Tormo, N., Bayona, J. V. M., García, M. M. M., Rodríguez, D. N., Álvarez, M. B., Serrano, M. D. R. G., & Cardona, C. G. (2020) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2020.02.007 · Cited by 39
Garcia-Bustos, V., Pemán, J., Ruiz-Gaitán, A., Cabañero-Navalon, M. D., Cabanilles-Boronat, A., Fernández-Calduch, M., Marcilla-Barreda, L., Sigona-Giangreco, I. A., Salavert, M., Tormo-Mas, M. Á., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2017756 · Cited by 30
Transcriptional and translational landscape of Candida auris in response to caspofungin
Zamith-Miranda, D., Amatuzzi, R. F., Munhoz da Rocha, I. F., Martins, S. T., Lucena, A. C. R., Vieira, A. Z., Trentin, G., Almeida, F., Rodrigues, M. L., Nakayasu, E. S., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.09.007 · Cited by 29
Native human and mouse skin infection models to study Candida auris-host interactions
Seiser, S., Arzani, H., Ayub, T., Phan-Canh, T., Staud, C., Worda, C., Kuchler, K., & Elbe-Bürger, A. (2024) · Microbes and Infection · doi:10.1016/j.micinf.2023.105234 · Cited by 29
Malavia-Jones, D., Farrer, R. A., Stappers, M. H. T., Edmondson, M. B., Borman, A. M., Johnson, E. M., Lipke, P. N., & Gow, N. A. R. (2023) · The Cell Surface · doi:10.1016/j.tcsw.2023.100110 · Cited by 29
Review of treatment options for a multidrug-resistant fungus: Candida auris
Wang, S., Pan, J., Gu, L., Wang, W., Wei, B., Zhang, H., Chen, J., & Wang, H. (2023) · Medical Mycology · doi:10.1093/mmy/myad127 · Cited by 34
Skin and hard surface disinfection against Candida auris – What we know today
Omardien, S., & Teska, P. J. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1312929 · Cited by 36
Uniqueness of Candida auris cell wall in morphogenesis, virulence, resistance, and immune evasion
Dakalbab, S., Hamdy, R., Holigová, P., Abuzaid, E. J., Abu-Qiyas, A., Lashine, Y., Mohammad, M. G., & Soliman, S. S. M. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127797 · Cited by 31
Mallick, D. C., Kaushik, N., Goyal, L., Mallick, L., & Singh, P. K. (2025) · Diseases · doi:10.3390/diseases13040093 · Cited by 35
“C. auris exhibits intrinsic resistance to multiple antifungal classes, earning its classification as a multidrug-resistant species. domain—can now accurately identify C. auris [31,32].”
Hsu, C., & Yassin, M. (2025) · Microorganisms · doi:10.3390/microorganisms13071461 · Cited by 34
“WGS enables the differentiation of local transmission from new introductions by comparing single nucleotide polymorphisms (SNPs) across isolates [112].”
Methods for identification of Candida auris, the yeast of global public health concern: A review
Mahmoudi, S., Afshari, S. A. K., Gharehbolagh, S. A., Mirhendi, H., & Makimura, K. (2019) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2019.04.004 · Cited by 33
“auris have been identified, which appear to have emerged independently [10].”
BackgroundA detailed lipidomic study of human pathogenic fungi Candida auris
Shahi, G., Kumar, M., Kumari, S., Rudramurthy, S. M., Chakrabarti, A., Gaur, N. A., Singh, A., & Prasad, R. (2020) · FEMS Yeast Research · doi:10.1093/femsyr/foaa045 · Cited by 32
“…due to C. auris, now prevalent worldwide, is associated with a high mortality rate and treatment failure, in addition to being highly resistant to commonly used antimycotics such as azoles, polyenes, and echinocandins (Chowdhary, Sharma and Meis 2017; Lockhart et al. 2017; Lone and Ahmad 2019).”
BackgroundPla, L., Santiago‐Felipe, S., Tormo‐Más, M. Á., Gaitán, A. C. R., Pemán, J., Valentín, E., Sancenón, F., Aznar, E., & Martínez‐Máñez, R. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1870411 · Cited by 31
“logenetic relationships using single nucleotide polymorphism (SNP) analysis [34].”
MethodFirst reported outbreak of the emerging pathogen Candida auris in Canada
Eckbo, E. J., Wong, T., Bharat, A., Cameron-Lane, M., Hoang, L., Dawar, M., & Charles, M. (2021) · American Journal of Infection Control · doi:10.1016/j.ajic.2021.01.013 · Cited by 34
Antifungal activity of nikkomycin Z against Candida auris
Bentz, M. L., Nunnally, N. S., Lockhart, S. R., Sexton, D. J., & Berkow, E. L. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab052 · Cited by 29
Self-citationPreliminary Characterization of NP339, a Novel Polyarginine Peptide with Broad Antifungal Activity
Duncan, V., Smith, D., Simpson, L., Lovie, E., Katvars, L., Berge, L., Robertson, J., Smith, S., Munro, C. A., Mercer, D., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02345-20 · Cited by 30
Rosario-Colon, J., EBERLE, K. E., Adams, A., Courville, E., & Xin, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116162 · Cited by 31
“auris isolates can be grouped into five clades (I-V) originating from different geographic regions [4].”
BackgroundInfluentialImmunopathogenesis of Emerging Candida auris and Candida haemulonii Strains
Pharkjaksu, S., Boonmee, N., Mitrpant, C., & Ngamskulrungroj, P. (2021) · Journal of Fungi · doi:10.3390/jof7090725 · Cited by 31
“haemulonii responses after infection are largely unknown [16].”
BackgroundWilliamson, B., Wilk, A. S., Guerrero, K. D., Mikulski, T. D., Elias, T. N., Sawh, I., Cancino-Prado, G., Gardam, D., Heath, C. H., Govender, N. P., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01624-21 · Cited by 30
Self-citationBing, J., Wang, S., Xu, H., Fan, S., Du, H., Nobile, C. J., & Huang, G. (2021) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2021.1994479 · Cited by 30
Roberto, T. N., de Carvalho, J. A., Beale, M. A., Hagen, F., Fisher, M. C., Hahn, R. C., Camargo, Z. P. D., & Rodrigues, A. M. (2021) · Studies in Mycology · doi:10.1016/j.simyco.2021.100131 · Cited by 33
“Convergence between fi ngerprints and genomic methods has already been demonstrated for Candida auris using AFLP (Schelenz et al. 2016), short tandem repeat typing (de Groot et al. 2020), and whole-genome sequencing (Lockhart et al. 2017).”
Priya, A., Nivetha, S., & Pandian, S. K. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.780545 · Cited by 30
Emergence and Genomic Characterization of Multidrug Resistant Candida auris in Nigeria, West Africa
Oladele, R. O., Uwanibe, J. N., Olawoye, I. B., Ettu, A.-W. O.-O., Meis, J. F. G. M., & Happi, C. T. (2022) · Journal of Fungi · doi:10.3390/jof8080787 · Cited by 36
“auris emerged independently at different geographical points across the world [27], and our phylogenetic analysis implies that there might have been at least two different introductions of C.”
BackgroundSelf-citationIntestinal bacteria—a powerful weapon for fungal infections treatment
Cong, L., Chen, C., Mao, S., Han, Z., Zhu, Z., & Li, Y. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1187831 · Cited by 30
“Frontiers in Cellular and Infection Microbiology 02 persistently (Schelenz et al., 2016; Lockhart et al., 2017; Vallabhaneni et al., 2017).”
BackgroundCeragenins as Mimics of Endogenous Antimicrobial Peptides
Hashemi, M., Holden, B., DurnaAA, B., Buck, R., & Savage, P. B. (2017) · Journal of Antimicrobial Agents · doi:10.4172/2472-1212.1000141 · Cited by 31
“Due to emerging resistance of fungi to commonly used antibiotics, the need for development of novel effective antifungal agents has become increasingly recognized [69-71].”
BackgroundCoERG11 A395T mutation confers azole resistance in Candida orthopsilosis clinical isolates
Rizzato, C., Poma, N. V., Zoppo, M., Posteraro, B., Mello, E., Bottai, D., Lupetti, A., Sanguinetti, M., & Tavanti, A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky122 · Cited by 29
Metadata
- Authors
- Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., Berkow, E. L., Castanheira, M., Magobo, R. E., Jabeen, K., Asghar, R. J., Meis, J. F., Jackson, B., Chiller, T., & Litvintseva, A. P.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Aga Khan University (PK)
- University of Delhi (IN)
- National Health Laboratory Service (ZA)
- Universidade Federal de São Paulo (BR)
- Universidad del Zulia (VE)
- Broad Institute (US)
- JMI Laboratories (US)
- Radboud University Nijmegen (NL)
- ORCID
- Lockhart, Shawn R.
- Vallabhaneni, Snigdha
- Farooqi, Joveria
- Chowdhary, Anuradha
- Govender, Nelesh P.
- Colombo, Arnaldo Lopes
- Cuomo, Christina A.
- Desjardins, Christopher A.
- Berkow, Elizabeth L.
- Castanheira, Mariana
- Magobo, Rindidzani E.
- Jabeen, Kauser
- Asghar, Rana J.
- Meis, Jacques F.
- Jackson, Brendan
- Chiller, Tom
- Litvintseva, Anastasia P.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10-20
- Volume
- 64
- Issue
- 2
- Pages
- 134-140
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC5215215
- OpenAlex
- W2536287248
- Semantic Scholar
- c8d8e54651d8fb7a7ece68270cd2630d1cd0df39
- Cited by
- 1,662
- References
- 32
- Citations by year
- 2026: 196 · 2025: 194 · 2024: 203 · 2023: 186 · 2022: 160 · 2021: 178 · 2020: 187 · 2019: 152 · 2018: 116 · 2017: 81 · 2016: 5
- FWCI
- 108.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- public-domain
- Locations
- Clinical Infectious Diseases (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (U19AI110818)
- United States Agency for International Development (4-338/PAK-US/HEC/2010/932)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- Candida auris, multidrug resistance, antifungal resistance, clonal populations, ERG11 mutations, azole resistance, fluconazole resistance, bloodstream infection, invasive candidiasis, nosocomial infections, risk factors, transmission, whole genome sequencing, antifungal susceptibility
- MeSH terms
- Whole Genome Sequencing, Adolescent, Adult, Aged, Antifungal Agents, Candida, Candidiasis, Child, Child, Preschool, Cytochrome P-450 Enzyme System, Female, Humans, Infant, Infant, Newborn, Male, Microbial Sensitivity Tests, Middle Aged, Mutation, Phylogeny, RNA, Ribosomal, 28S, Global Health, Genome, Fungal, Drug Resistance, Multiple, Polymorphism, Single Nucleotide, DNA, Ribosomal Spacer, Drug Resistance, Fungal, Young Adult, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.